(Q37767875)

22 August 2017

1 reference

title

The ubiquitin-proteasome system in prostate cancer and its transition to castration resistance (English)

1 reference

ubiquitin-proteasome system

22 August 2017

main subject

0 references

1 reference

Ioannis A. Voutsadakis

series ordinal

1

object named as

Ioannis A Voutsadakis

1 reference

22 August 2017

author name string

Christos N Papandreou

series ordinal

2

1 reference

22 August 2017

publication date

26 June 2010

1 reference

22 August 2017

1 reference

22 August 2017

volume

30

1 reference

22 August 2017

issue

6

1 reference

22 August 2017

page(s)

752-761

1 reference

The role of prevalence in the diagnosis of prostate cancer

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Controversies surrounding androgen deprivation for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

A pilot study of intermittent androgen deprivation in advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

The development of androgen-independent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Activation of the human androgen receptor through a protein kinase A signaling pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

The ubiquitin-proteasome pathway and its role in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

The proteasome: a novel target for cancer chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Pathogenesis of colorectal carcinoma and therapeutic implications: the roles of the ubiquitin-proteasome system and Cox-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

The proteasome: a proteolytic nanomachine of cell regulation and waste disposal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

APC/C and SCF: controlling each other and the cell cycle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Mechanisms and regulation of the degradation of cyclin B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Caspase activation inhibits proteasome function during apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Caspase-dependent inactivation of proteasome function during programmed cell death in Drosophila and man.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

To live or die by the sword: the regulation of apoptosis by the proteasome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Control of androgen receptor signaling in prostate cancer by the cochaperone small glutamine rich tetratricopeptide repeat containing protein alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Essential role for Co-chaperone Fkbp52 but not Fkbp51 in androgen receptor-mediated signaling and physiology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Heat shock protein 27 mediates repression of androgen receptor function by protein kinase D1 in prostate cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

The program of androgen-responsive genes in neoplastic prostate epithelium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Cooperative assembly of androgen receptor into a nucleoprotein complex that regulates the prostate-specific antigen enhancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Diverse roles of androgen receptor (AR) domains in AR-mediated signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

A common motif targets huntingtin and the androgen receptor to the proteasome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Degradation and beyond: control of androgen receptor activity by the proteasome system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Peroxisome proliferator-activated receptor gamma (PPARgamma) and colorectal carcinogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Linking the ubiquitin-proteasome pathway to chromatin remodeling/modification by nuclear receptors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Intersection of nuclear receptors and the proteasome on the epigenetic landscape

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Dynamic combinatorial networks in nuclear receptor-mediated transcription

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Nuclear receptor coregulators and human disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Nuclear receptor interaction protein, a coactivator of androgen receptors (AR), is regulated by AR and Sp1 to feed forward and activate its own gene expression through AR protein stability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Steroid receptor induction of gene transcription: a two-step model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Transcriptional regulation by histone ubiquitination and deubiquitination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Methylation of histone H3 by COMPASS requires ubiquitination of histone H2B by Rad6.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Ubiquitination of histone H2B regulates H3 methylation and gene silencing in yeast

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

H2B ubiquitylation in transcriptional control: a FACT-finding mission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Proteasomal ATPases link ubiquitylation of histone H2B to methylation of histone H3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Human PIRH2 enhances androgen receptor signaling through inhibition of histone deacetylase 1 and is overexpressed in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Structural basis of eukaryotic gene transcription

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Removal of promoter nucleosomes by disassembly rather than sliding in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

TBL1 and TBLR1 phosphorylation on regulated gene promoters overcomes dual CtBP and NCoR/SMRT transcriptional repression checkpoints

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

E6-associated protein (E6-AP) is a dual function coactivator of steroid hormone receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

A coregulatory role for the mediator complex in prostate cancer cell proliferation and gene expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Emerging roles of ubiquitin in transcription regulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

TSG101 interacts with apoptosis-antagonizing transcription factor and enhances androgen receptor-mediated transcription by promoting its monoubiquitination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Involvement of proteasome in the dynamic assembly of the androgen receptor transcription complex.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Persistent intraprostatic androgen concentrations after medical castration in healthy men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

The androgen axis in recurrent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Mechanisms underlying the development of androgen-independent prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

AR, the cell cycle, and prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Molecular determinants of resistance to antiandrogen therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Involvement of neutral endopeptidase in neoplastic progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Loss of neutral endopeptidase and activation of protein kinase B (Akt) is associated with prostate cancer progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Identification and characterization of two androgen response regions in the human neutral endopeptidase gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Neutral endopeptidase inhibits prostate cancer cell migration by blocking focal adhesion kinase signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Synergy in tumor suppression by direct interaction of Neutral Endopeptidase with PTEN

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Chemosensitization of androgen-independent prostate cancer with neutral endopeptidase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Phosphorylation is required for PMA- and cell-cycle-induced degradation of protein kinase Cdelta.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Proteasome‐dependent decrease in Akt by growth factors in vascular smooth muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Neutral endopeptidase protein expression and prognosis in localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Nuclear insulin-like growth factor binding protein-3 induces apoptosis and is targeted to ubiquitin/proteasome-dependent proteolysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Up-regulation of Skp2 after prostate cancer cell adhesion to basement membranes results in BRCA2 degradation and cell proliferation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Role of the F-box protein Skp2 in adhesion-dependent cell cycle progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

How nucleotide excision repair protects against cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Ets proteins in biological control and cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Regulation of vascular inflammation and remodeling by ETS factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

New androgen receptor genomic targets show an interaction with the ETS1 transcription factor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Wnt signalling and the mechanistic basis of tumour development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Linking beta-catenin to androgen-signaling pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

The androgen receptor can signal through Wnt/beta-Catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

HSP27 is a ubiquitin-binding protein involved in I-kappaBalpha proteasomal degradation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Clusterin facilitates COMMD1 and I-kappaB degradation to enhance NF-kappaB activity in prostate cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Bortezomib as a potential treatment for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Bortezomib (PS-341): A Novel, First-in-Class Proteasome Inhibitor for the Treatment of Multiple Myeloma and Other Cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Proteasome inhibitor PS-341 down-regulates prostate-specific antigen (PSA) and induces growth arrest and apoptosis of androgen-dependent human prostate cancer LNCaP cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Proteasome inhibition blocks caspase-8 degradation and sensitizes prostate cancer cells to death receptor-mediated apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Proteasome activity is required for androgen receptor transcriptional activity via regulation of androgen receptor nuclear translocation and interaction with coregulators in prostate cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Proteasome inhibitors induce apoptosis of prostate cancer cells by inducing nuclear translocation of IkappaBalpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

YC-1 suppresses constitutive nuclear factor-kappaB activation and induces apoptosis in human prostate cancer cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

MG-132 sensitizes TRAIL-resistant prostate cancer cells by activating c-Fos/c-Jun heterodimers and repressing c-FLIP(L).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DR5 mRNA through the 3'-untranslated region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Proteasome inhibitor MG132 induces death receptor 5 through CCAAT/enhancer-binding protein homologous protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Neonatal estrogen down-regulates prostatic androgen receptor through a proteosome-mediated protein degradation pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

Development of Protacs to Target Cancer-promoting Proteins for Ubiquitination and Degradation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.013

10.1016/J.UROLONC.2010.03.013

7 January 2021

Identifiers

DOI

1 reference

22 August 2017

1 reference